4D Molecular touts 4D‑150 momentum

4D Molecular Therapeutics told investors in May that its retinal gene therapy candidate 4D-150 is no longer just an early-stage durability story. The Emeryville, California-based company said wet age-related macular degeneration, or wet AMD, is already in Phase 3 development and diabetic macular edema, or DME, is the next registrational push. The update came through the company’s investor materials and first-quarter 2026 results, where management laid out a sequence of milestones rather than announcing new clinical data. The message was that 4D-150 is being positioned for two large retinal disease markets, with wet AMD further along than DME. ### How far along is 4D-150 in wet AMD right now? May 7 marked the clearest status update. 4DMT said 4FRONT-1, one of its Phase 3 wet AMD studies, had completed randomization with 523 patients after enrollment finished in February 2026 and randomization finished in March 2026. The company said topline data from that study are expected in the first half of 2027. (4dmt.gcs-web.com) March 10, 2025, was the date 4DMT disclosed first patient enrollment in 4FRONT-1. In that release, the company said the trial was designed as a randomized, double-masked study against aflibercept 2 mg every eight weeks, with a primary endpoint of non-inferiority in best corrected visual acuity at 52 weeks and a key secondary endpoint measuring reduction in injection burden. (markets.businessinsider.com) 4DMT also said 4FRONT-2, the second Phase 3 wet AMD study, is expected to complete enrollment in the second half of 2026, with topline data expected in the second half of 2027. That means the wet AMD program is already in confirmatory testing, not merely in planning. (ir.4dmoleculartherapeutics.com) ### What is the company actually claiming for DME? May 7 investor materials said the DME program is on a different timeline. 4DMT said SPECTRA two-year data are expected in the second half of 2026, a global Phase 3 trial design is expected in mid-2026, and trial initiation is expected in the third quarter of 2026. (markets.businessinsider.com) July 31, 2025, was the company’s last detailed DME update in the materials reviewed here. 4DMT said then that the European Medicines Agency had aligned with a proposed single Phase 3 trial being acceptable for regulatory submission in DME, consistent with what the company said was prior alignment with the U.S. Food and Drug Administration. (markets.businessinsider.com) The same July 2025 release said the Phase 3 dose in SPECTRA achieved a 78% reduction in treatment burden versus projected on-label aflibercept 2 mg every eight weeks. Those figures came from the company’s trial presentation and were part of management’s case for moving DME into a registrational study. (biospace.com) ### What problem is 4D-150 supposed to solve? 4DMT describes 4D-150 as a single intravitreal gene therapy designed to provide sustained delivery of anti-VEGF components over multiple years. In its investor materials, the company said the goal is to reduce the burden of repeated bolus injections that patients with retinal vascular disease now receive under standard care. David Kirn, 4DMT’s co-founder and chief executive, said in the company’s March 2025 Phase 3 launch statement that wet AMD and DME share what he called the “greatest unmet needs” of multi-year relief from frequent injections and preservation of eyesight. (biospace.com) David Almeida of Erie Retina Research, presenting SPECTRA data in 2025, said durable activity in DME could reduce treatment burden versus labeled aflibercept dosing. Those are company-aligned and investigator-attributed claims, not regulatory findings. (4dmt.gcs-web.com) ### Is this a new practice-changing result? May 2026 materials reviewed for this story did not announce a new pivotal efficacy readout. The company’s recent communication was mainly a development-status update: one wet AMD Phase 3 trial randomized, another still enrolling, and DME being prepared for Phase 3. (ir.4dmoleculartherapeutics.com) Market commentary circulating after the investor update framed the message as momentum rather than a change in standard of care. The underlying milestones that can test the company’s claims are more concrete: PRISM two-year wet AMD data in the third quarter of 2026, SPECTRA two-year DME data in the second half of 2026, and the first wet AMD Phase 3 topline readout in the first half of 2027. (markets.businessinsider.com) ### What should readers watch next? Mid-2026 is the next stated checkpoint for DME. 4DMT said it expects to finalize a global Phase 3 trial design then, followed by trial initiation in the third quarter of 2026. The first hard late-stage test in wet AMD is scheduled for the first half of 2027, when 4DMT expects topline data from 4FRONT-1. (markets.businessinsider.com) As of March 31, 2026, the company said it had $458 million in cash, cash equivalents and marketable securities and expected that cash to fund its operating plan into the second half of 2028.